AZD4747 / AstraZeneca - LARVOL DELTA

Validation of a good manufacturing practice procedure for the production of [ C]AZD4747, a CNS penetrant KRAS inhibitor. (PubMed, J Labelled Comp Radiopharm) - "The validated procedure afforded [ C]AZD4747 as an injectable solution in good radioactivity yield (1656 ± 532 MBq), excellent radiochemical purity (100%), and a molar activity of 77 ± 13 GBq/μmol at the end of the synthesis, which took 46 ± 1 min from the end of the bombardment. Quality control on the final product was performed satisfactorily and met all acceptance criteria."

Journal • KRAS